Follicular Lymphoma

News alerts, weekly reports and conference planners

Related cancers:

No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	obinutuzumab Sensitive: A1 - Approval obinutuzumab Sensitive : A1	obinutuzumab Sensitive: A1 - Approval obinutuzumab Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1
CD20 positive	Follicular Lymphoma	CD20 positive	Follicular Lymphoma	rituximab + ibritumomab tiuxetan Sensitive: A1 - Approval rituximab + ibritumomab tiuxetan Sensitive : A1	rituximab + ibritumomab tiuxetan Sensitive: A1 - Approval rituximab + ibritumomab tiuxetan Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	ibritumomab tiuxetan Sensitive: A1 - Approval ibritumomab tiuxetan Sensitive : A1	ibritumomab tiuxetan Sensitive: A1 - Approval ibritumomab tiuxetan Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	idelalisib Sensitive: A1 - Approval idelalisib Sensitive : A1	idelalisib Sensitive: A1 - Approval idelalisib Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	duvelisib Sensitive: A1 - Approval duvelisib Sensitive : A1	duvelisib Sensitive: A1 - Approval duvelisib Sensitive : A1
EZH2 wild-type	Follicular Lymphoma	EZH2 wild-type	Follicular Lymphoma	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1
EZH2 mutation	Follicular Lymphoma	EZH2 mutation	Follicular Lymphoma	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	copanlisib Sensitive: A1 - Approval copanlisib Sensitive : A1	copanlisib Sensitive: A1 - Approval copanlisib Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	umbralisib Sensitive: A1 - Approval umbralisib Sensitive : A1	umbralisib Sensitive: A1 - Approval umbralisib Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1
CD20 positive	Follicular Lymphoma	CD20 positive	Follicular Lymphoma	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab/hyaluronidase Sensitive: A1 - Approval rituximab / hyaluronidase Sensitive : A1	rituximab/hyaluronidase Sensitive: A1 - Approval rituximab / hyaluronidase Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	R-CHOP Sensitive: A2 - Guideline R-CHOP Sensitive : A2	R-CHOP Sensitive: A2 - Guideline R-CHOP Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	R-CVP Sensitive: A2 - Guideline R-CVP Sensitive : A2	R-CVP Sensitive: A2 - Guideline R-CVP Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab + obinutuzumab Sensitive: A2 - Guideline rituximab + obinutuzumab Sensitive : A2	rituximab + obinutuzumab Sensitive: A2 - Guideline rituximab + obinutuzumab Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	chlorambucil Sensitive: A2 - Guideline chlorambucil Sensitive : A2	chlorambucil Sensitive: A2 - Guideline chlorambucil Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	lenalidomide + obinutuzumab Sensitive: A2 - Guideline lenalidomide + obinutuzumab Sensitive : A2	lenalidomide + obinutuzumab Sensitive: A2 - Guideline lenalidomide + obinutuzumab Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	cyclophosphamide Sensitive: A2 - Guideline cyclophosphamide Sensitive : A2	cyclophosphamide Sensitive: A2 - Guideline cyclophosphamide Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	G-CHOP Sensitive: A2 - Guideline G-CHOP Sensitive : A2	G-CHOP Sensitive: A2 - Guideline G-CHOP Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	CG-781 Sensitive: B - Late Trials CG-781 Sensitive : B	CG-781 Sensitive: B - Late Trials CG-781 Sensitive : B
BCL2 elevation + IGH elevation	Follicular Lymphoma	BCL2 elevation + IGH elevation	Follicular Lymphoma	rituximab Resistant: B - Late Trials rituximab Resistant : B	rituximab Resistant: B - Late Trials rituximab Resistant : B
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	INCB50465 Sensitive: B - Late Trials INCB50465 Sensitive : B	INCB50465 Sensitive: B - Late Trials INCB50465 Sensitive : B
TMB-L	Follicular Lymphoma	TMB-L	Follicular Lymphoma	rituximab Sensitive: B - Late Trials rituximab Sensitive : B	rituximab Sensitive: B - Late Trials rituximab Sensitive : B
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	mosunetuzumab Sensitive: B - Late Trials mosunetuzumab Sensitive : B	mosunetuzumab Sensitive: B - Late Trials mosunetuzumab Sensitive : B

Follicular Lymphoma

Associations(73)

Associations
(73)